🇺🇸 FDA
Pipeline program

APL-2

APL2-GA-305

Phase 3 small_molecule active

Quick answer

APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Geographic Atrophy Secondary to Age-Related Macular Degeneration
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials